To assess shifts in phenotypic effector profiles, we first analyzed ex vivo flow cytometry data of CD4+ Th cells from paired third trimester and early postpartum blood of healthy controls (n = 12; HC) and MS patients without a postpartum relapse (n = 13; MS-NR) in an unbiased manner using HSNE (Figure 1A and Supplementary Figure 1). This evidence concerns the gene CD4 and myeloid sarcoma.